This study aimed at defining clinical predictors of drug resistance in adults with genetic generalized epilepsy (GGE) who were treated with a broad spectrum of antiepileptic drugs. Of a cohort of 137 unselected adult GGE patients with long-term follow up, clinical and demographic data, putative prognostic factors (e.g., psychiatric comorbidities, electroencephalography [EEG]), treatment response, and data indicative of social status were collected. Fifty-eight patients had seizures within the past year. Thirty-three patients met the definition of "drug-resistant epilepsy" according to the International League Against Epilepsy (ILAE) definition. Psychiatric comorbidities, age at first diagnosis, and absences were associated with worse seizure control, whereas focal changes in EEG remained without prognostic impact. Resistance to valproic acid was the most important prognostic factor for refractory seizures. Resistance to valproic acid had a specificity of 100% to identify patients with drug resistance and correlated strongly with bad social outcome and seizure burden. Conversely, 21.2% of all patients with refractory seizures according to the ILAE definition later became seizure free (mainly with valproic acid). Our data suggest that "drug resistant GGE" must not be declared unless patients were adequately treated with valproic acid, and advocate resistance to valproic acid as a new clinical biomarker for drug-resistant GGE.
Genetic generalized epilepsy (GGE; also called idiopathic generalized epilepsy) accounts for 15-20% of all epilepsies. The International League against Epilepsy (ILAE) currently recognizes eight epileptic syndromes under the name of GGE; three of them are of clinical relevance in adults: juvenile absence epilepsy (JAE), juvenile myoclonic epilepsy (JME), and epilepsy with generalized tonic-clonic seizures only (EGTC).
Although most patients with GGE have a good prognosis and normal cognitive development, 1 16-36% of all patients (depending on the definition and the cohort studied) remain drug resistant. 2 Little is known about patients with refractory GGE. All clinical syndromes comprise refractory and responsive patients. Many landmark papers were published before newer antiepileptic drugs (AEDs) became available or had a relatively small patient number. [3] [4] [5] Szaflarski et al. 6 recently suggested that focality on electroencephalography (EEG), and the presence of focal seizures other than the typical, syndrome-associated seizures may be associated with resistance to valproic acid. However, this hypothesis is controversial. 1 Furthermore, the endophenotypes defined by more than two seizure types (myoclonic seizures, absences, generalized tonic-clonic seizures) and praxis-induced seizures in adult patients with GGE may indicate worse response to medical treatment. 7 The consensus on the definition of drug-resistant epilepsy reliably identifies patients with highly drug-resistant focal epilepsy. 8 The applicability of this definition to GGE patients and risk factors associated with the development of drug-resistant epilepsy based on the ILAE definition have not yet been thoroughly studied. In this study, we aimed at identifying clinical risk factors associated with treatment resistance defined by the International League Against Epilepsy (ILAE), allowing for an early identification of patients with difficult-to-treat epilepsy.
Materials and Methods

Patient cohort
The study was conducted as a retrospective cohort study at the Epilepsy Clinic at Odense University Hospital, Denmark, and approved by the local Data Protection Agency. We consecutively recruited all patients who were previously or newly diagnosed with GGE in our department. We did not select patients. A total of 150 consecutive patients were approached at their scheduled appointments and gave written informed consent for study participation. Missing data were sought and completed at the scheduled appointment after informed consent was obtained. We then extracted baseline data and treatment outcome as well as seizure types and EEG. One hundred thirty-seven patients fulfilled the inclusion criteria (see also Fig. S1 ).
The diagnosis GGE was based on semiology, imaging, and EEG. All EEG studies were analyzed by a board certified neurophysiologist. The subclassification (EGTC, JME, JAE) was performed based on the predominant seizure type. , and ethosuximide were considered to be "correctly chosen drugs." If the patient became seizure free under treatment with a given drug but could not continue treatment due to side effects or pregnancy, the patient was classified as "responsive" to the given drug. Based on the documented seizure activity, we estimated the occupational hazard score. 9 
Statistical analysis
The groups were compared using the Wilcoxon rank-sum test for numerical data and the chi-square test or Fisher's exact test for categorical data. We used a 0.05 significance level. The statistical analyses were performed using the statistic software package "R" version 2.15.2 (www.r-pro ject.org) and SPSS 21. Table S1 gives an overview of the patient cohort. The average age was 36.3 years; 63% of the study population consisted of women and almost all of the patients were Danish citizens. We classified patients as EGTC (43.8%), JME (36.5%), and JAE (19.7%, including two patients with Jeavons syndrome). EEG was available for 96.4% of the study population, of which 89.4% showed typical spikewave activity of 3-5/s. MRI/CT was available for 62% of all patients and was normal or with minor changes in all but two patients (hippocampal atrophy/subependymal noduli, EEG, and semiology of seizures were thought otherwise typical for GGE).
Results
Patient characteristics
Control of epileptic seizures
All AEDs approved by the European Medical Agency (EMA) are available for treatment of patients with refractory epilepsy in Denmark. Table S2 shows the drugs used for treatment; 57.6% of the study population became completely seizure free defined as lack of seizures in >1 year on current therapy (under both monotherapy and polytherapy), and 12.4% of the all patients were "pseudo-resistant" (i.e., recurrent seizures due to incompliance to treatment, use of alcohol, heavy sleep restriction). Of all patients, 30% were uncontrolled due to insufficient effect of the ongoing antiepileptic treatment.
Among the seizure-free patients, 74% were on monotherapy and 25% were on polytherapy. Thirteen percent had tried more than two drugs before current treatment. Twentyfive percent of the seizure-free patients had tried valproic acid before current treatment, of which half of the patients stopped due to side effects (mainly weight gain, tremor) or pregnancy.
Predictors of drug-resistant epilepsy
A total of 24.1% of all patients fulfilled the ILAE criteria for being drug resistant at one time point, that is, they had a seizure despite of treatment with two correctly chosen drugs in sufficient doses. 8 To identify clinical predictors of drug resistance, we analyzed all clinical factors assessed in our study, and compared them in seizure-free patients and patients with treatment refractory epilepsy according to the ILAE criteria. Resistance to valproic acid treatment was the factor with the highest association with drug-resistant epilepsy ( Table 1) . Nine of 33 patients with drug refractory epilepsy did not try or could not tolerate valproic acid (exclusively young women). A more detailed analysis unveiled that all patients being resistant to valproic acid were also drug resistant according to the ILAE definition despite higher daily doses used (Table 1) . In our cohort, resistance to valproic acid had a specificity of 100% and a positive predictive value of 100% for drug resistance according to the ILAE definition. In addition, psychiatric comorbidity, age at diagnosis, current/former substance abuse, and diagnosis of JAE/absences bore prognostic relevance. Focality in EEG and presence of all three seizure types did not reach statistical significance. Comparison of surrogate markers of social outcome in patients with valproic acid-resistant GGE and drugresistant epilepsy according to the ILAE definition None of the patients with resistance to valproic acid, but 21.4% of the patients fulfilling the ILAE classification of drug-resistant epilepsy at one time point became seizure free later on. Of these, five became seizure free under treatment with valproic acid, and one patient became seizure free under treatment with levetiracetam or topiramate. We therefore speculated that resistance to valproic acid might be superior to the ILAE definition in identifying patients with bona fide refractory GGE. When looking at surrogate markers of social outcome, patients resistant to valproic acid were more severely affected in all parameters studied. They were more likely to have psychiatric and somatic comorbidities, had a higher seizure activity (as determined in the occupational hazard score), were less likely to live in a stable relationship, and had a lower chance of obtaining a college degree. There were no differences in age, gender, or ethnicity (Table 2 ).
Discussion
Our study not only confirmed the clinical experience suggesting that valproic acid is the most effective drug for the treatment of GGE, but it also suggests that resistance to valproic acid defines patients with drug-resistant GGE better than the current ILAE definition does. Of course, this retrospective cohort study has by its nature shortcomings: Patients with higher seizure activity may be overrepresented in our study population, and the available retrospective data Resistance to Valproic Acid in GGE are certainly inferior to a prospective trial. Still, our cohort includes many patients treated over decades in the same department with standardized long-term documentation of treatment, side effects, and compliance. In contrast to previous studies, our patients were treated with the entire spectrum of AEDs available. 3 However, this did not improve the patients' prognosis with respect to seizure control: Patients who did not respond to valproic acid remained nonresponders to any other drug tried, which is the main message of this publication and which is not affected by the typical flaws of retrospective studies.
Our findings are in line with data reported by Nicolson et al. 10 They retrospectively analyzed a cohort of 962 patients with idiopathic generalized epilepsy treated with lamotrigine, valproic acid, and topiramate. In the discussion, the authors mention that none of the patients who were resistant to valproic acid responded to lamotrigine or topiramate. In our cohort, the use of levetiracetam and zonisamide or other drugs did not improve the prognosis either.
In Europe, most young female patients receive lamotrigine and levetiracetam as first-line treatment due to favorable side effects. 11 If this treatment fails, the patients have to be declared "drugs resistant" according to the ILAE definition. 8 However, in our population, most of these patients later responded to valproic acid, suggesting that patients with GGE must not be declared "drug resistant" unless valproic acid has been adequately tried. The higher risk for bad social outcome and high seizure burden certainly supports this hypothesis, irrespective of the fact that a prospective assessment of quality of life would certainly have strengthened this part of our study.
Little is known about the mechanism behind drug-resistant GGE. We could not reproduce findings by Szarflawski et al., who suggested that resistance to valproic acid was due to focality in the EEG. However, we did not systematically reevaluate all EEG and excluded all patients with typical focal seizures, which impedes final conclusions to some extent. In contrast, we confirmed that patients with resistance to valproic acid have a higher risk for developing psychiatric diseases.
7,12 Even after we corrected for diseases that were possibly secondary to the high seizure burden (i.e., depression and anxiety), patients with valproic acidresistant epilepsy showed a significant higher psychiatric disease burden.
Valproic acid is not only the treatment of choice for GGE but is effective for treating psychiatric disorders, mainly bipolar disorders, and apparently not only prevents seizures. In healthy controls, 1,000 mg valproic acid resulted in a significant, region-specific decrease of blood oxygen level-dependent (BOLD) signal, irrespective of the paradigm used, suggesting that valproic acid modulates brain activation in a region-dependent manner. 13 In JME, working memory tasks led to a coactivation of the motor cortex and the supplementary motor area and an impaired deactivation of the default network. These alterations are modulated and may be normalized by valproic acid.
14 If one assumes that GGE is a network disease, 15 it is tempting to speculate that the superior effect of valproic acid may be due to its ability to modulate cerebral networks rather than to its antiepileptic properties alone.
In summary, we propose resistance to valproic acid as a new clinical biomarker for drug-resistant GGE and suggest that "drug-resistant GGE" must not be declared unless patients have been adequately treated with valproic acid.
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